Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 4
2005 4
2006 2
2007 11
2008 11
2009 5
2010 6
2011 11
2012 15
2013 13
2014 14
2015 18
2016 19
2017 11
2018 27
2019 19
2020 13
2021 14
2022 5
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study.
Shoji J, Goggins WC, Wellen JR, Cunningham PN, Johnston O, Chang SS, Solez K, Santos V, Larson TJ, Takeuchi M, Wang X. Shoji J, et al. Among authors: takeuchi m. Transplantation. 2024 Apr 1. doi: 10.1097/TP.0000000000004985. Online ahead of print. Transplantation. 2024. PMID: 38564451
Correlation of multiple endpoints in the first-line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials.
Arai H, Takeuchi M, Ichikawa W, Shitara K, Sunakawa Y, Oba K, Koizumi W, Sakata Y, Furukawa H, Yamada Y, Takeuchi M, Fujii M. Arai H, et al. Among authors: takeuchi m. Cancer Med. 2023 Dec 23;13(1):e6818. doi: 10.1002/cam4.6818. Online ahead of print. Cancer Med. 2023. PMID: 38140879 Free PMC article.
Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study.
Kodera Y, Yoshida K, Kochi M, Sano T, Ichikawa W, Kakeji Y, Sunakawa Y, Takeuchi M, Fujii M. Kodera Y, et al. Among authors: takeuchi m. Gastric Cancer. 2023 Nov;26(6):1063-1068. doi: 10.1007/s10120-023-01419-9. Epub 2023 Aug 7. Gastric Cancer. 2023. PMID: 37548812 Free PMC article. Clinical Trial.
Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
Kobayashi K, Masuda N, Mizuno T, Miura K, Tokuda Y, Yoshinami T, Kawaguchi H, Ohtani S, Saeki T, Toi M, Takeuchi M, Ito Y. Kobayashi K, et al. Among authors: takeuchi m. Breast Cancer Res Treat. 2023 Oct;201(3):409-415. doi: 10.1007/s10549-023-07030-x. Epub 2023 Jul 22. Breast Cancer Res Treat. 2023. PMID: 37480384 Clinical Trial.
Double-hit follicular lymphoma diagnosed due to central nervous system symptoms.
Kawajiri-Manako C, Mishina T, Tsujimura H, Maruyama S, Sato A, Sugawara T, Kumagai K, Nakamura R, Itami M, Takeuchi M. Kawajiri-Manako C, et al. Among authors: takeuchi m. Ann Hematol. 2023 May;102(5):1281-1282. doi: 10.1007/s00277-023-05181-x. Epub 2023 Mar 27. Ann Hematol. 2023. PMID: 36971807 No abstract available.
Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
Tanioka H, Shimada K, Tsuji A, Kochi M, Kim HM, Takahashi T, Denda T, Takagane A, Watanabe T, Kotaka M, Nakamura M, Sunakawa YU, Takeuchi M, Ichikawa W, Fujii M. Tanioka H, et al. Among authors: takeuchi m. Anticancer Res. 2022 May;42(5):2675-2681. doi: 10.21873/anticanres.15745. Anticancer Res. 2022. PMID: 35489740 Clinical Trial.
199 results